An Innovation Leader in Immuno-Dermatology

Mission

An R&D anchored immuno-dermatology focused company to redefine the treatment landscape, bringing transformative solutions to patients worldwide.

Learn more

Team

Our team of co-founders is comprised of experienced dermatology and scientific experts with a mission to redefine immuno-dermatology.

Learn more

Pipeline

Alys has an R&D pipeline enabled by multi-platform technologies with over a dozen active programs with potential to transform treatment landscape across dermatologic conditions.

Learn more

Latest News

Alys Pharmaceuticals doses first subject in Phase 1/1b trial of ALY-301, a first-in-class mast cell selective c-Kit inhibitor for Chronic Urticaria 30 October 2025 - Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces that the first subject has been dosed in a Phase 1/1b study of ALY-301, a first-in-class mast cell selective c-Kit inhibitor for the treatment of Cold Urticaria, a subtype of Chronic Inducible Urticaria (CIndU) that is also considered to be a good model for the broader Chronic Urticaria population.

Events

There are currently no upcoming events

An Innovation Leader in Immuno-Dermatology

Mission

Team

Pipeline

Latest News

Events

© Alys Pharmaceuticals, Inc.

Address

Useful links